Antimicrobials
Cefprozil

Cefprozil

C difficile risk
Medium
Oral Bioavailability
Excellent
Cost
PO: $

Dosing

>6 months15 mg/kg/dose PO q12h Dose limit: 1 g/day

≥2 years7.5 mg/kg/dose PO q12h

Severe: Reduce dose by 50%

General Information

Otitis media, pharyngitis/tonsilitis

ODB Funded (tablets, oral liquid)

1% to 10%:

  • Central nervous system: Dizziness (1%)

  • Dermatologic: Diaper rash (2%), genital pruritus (2%)

  • Gastrointestinal: Nausea (4%), diarrhea (3%), abdominal pain (1%), vomiting (1%)

  • Genitourinary: Vaginitis

  • Hepatic: Increased serum transaminases (2%)

  • Infection: Superinfection

  • Evaluate renal function before and during therapy

  • With prolonged therapy, monitor coagulation tests, CBC, and liver function tests periodically

  • Monitor for signs of anaphylaxis during first dose

  • Food delays cefprozil absorption

  • Management: May administer with food

Should be used as a 2nd line alternative to cefuroxime axetil